The rise of copyright’s blockbuster initially drove a surge for pharma, but recent developments present a murky outlook for shareholders. Off-patent competitors are eroding earnings, and persistent litigation add https://cecilypctp033340.bloggazza.com/39902882/sildenafil-and-the-pharmaceutical-industry-a-risky-bet